Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140

被引:131
作者
Earl, PL
Sugiura, W
Montefiori, DC
Broder, CC
Lee, SA
Wild, C
Lifson, J
Moss, B
机构
[1] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA
[2] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[3] Panacos Pharmaceut, Gaithersburg, MD 20877 USA
[4] NCI, Frederick Canc Res & Dev Ctr, Retroviral Pathogenesis Lab, AIDS Vaccine Program,SAIC, Frederick, MD 21702 USA
关键词
D O I
10.1128/JVI.75.2.645-653.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The biologically active form of the human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein is oligomeric. We previously described a soluble HIV-1 IIIB Env protein, gp140, with a stable oligomeric structure composed of uncleaved gp120 linked to the ectodomain of gp41 (P. L. Earl, C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R W Doms, and B. Moss, J, Virol. 68:3015-3026, 1994). Here we compared the antibody responses of rabbits to gp120 and gp140 that had been produced and purified in an identical manner. The gp140 antisera exhibited enhanced cross-reactivity with heterologous Env proteins as well as greater neutralization of HIV-1 compared to the gp120 antisera. To examine both immunogenicity and protective efficacy, we immunized rhesus macaques with oligomeric gp140. Strong neutralizing antibodies against a homologous virus and modest neutralization of heterologous laboratory-adapted isolates were elicited. No neutralization of primary isolates was observed. However, a substantial fraction of the neutralizing activity could not be blocked by a V3 loop peptide. After intravenous challenge with simian-HIV virus SHN-HXB2, three of the four vaccinated macaques exhibited no evidence of virus replication.
引用
收藏
页码:645 / 653
页数:9
相关论文
共 79 条
  • [21] A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
    Doranz, BJ
    Rucker, J
    Yi, YJ
    Smyth, RJ
    Samson, M
    Peiper, SC
    Parmentier, M
    Collman, RG
    Doms, RW
    [J]. CELL, 1996, 85 (07) : 1149 - 1158
  • [22] NATIVE OLIGOMERIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN ELICITS DIVERSE MONOCLONAL-ANTIBODY REACTIVITIES
    EARL, PL
    BRODER, CC
    LONG, D
    LEE, SA
    PETERSON, J
    CHAKRABARTI, S
    DOMS, RW
    MOSS, B
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (05) : 3015 - 3026
  • [23] Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein
    Earl, PL
    Broder, CC
    Doms, RW
    Moss, B
    [J]. JOURNAL OF VIROLOGY, 1997, 71 (04) : 2674 - 2684
  • [24] INDUCTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC CYTOLYTIC T-LYMPHOCYTE RESPONSES IN SERONEGATIVE ADULTS BY A NONREPLICATING, HOST-RANGE-RESTRICTED CANARYPOX VECTOR (ALVAC) CARRYING THE HIV-1(MN) ENV GENE
    EGAN, MA
    PAVLAT, WA
    TARTAGLIA, J
    PAOLETTI, E
    WEINHOLD, KJ
    CLEMENTS, ML
    SILICIANO, RF
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (06) : 1623 - 1627
  • [25] ANTIBODY-DEPENDENT CELLULAR CYTO-TOXICITY IS DIRECTED AGAINST BOTH THE GP120 AND GP41 ENVELOPE PROTEINS OF HIV
    EVANS, LA
    THOMSONHONNEBIER, G
    STEIMER, K
    PAOLETTI, E
    PERKUS, ME
    HOLLANDER, H
    LEVY, JA
    [J]. AIDS, 1989, 3 (05) : 273 - 276
  • [26] Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex
    Fouts, TR
    Binley, JM
    Trkola, A
    Robinson, JE
    Moore, JP
    [J]. JOURNAL OF VIROLOGY, 1997, 71 (04) : 2779 - 2785
  • [27] Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
    Gauduin, MC
    Parren, PWHI
    Weir, R
    Barbas, CF
    Burton, DR
    Koup, RA
    [J]. NATURE MEDICINE, 1997, 3 (12) : 1389 - 1393
  • [28] FINE MAPPING OF AN IMMUNODOMINANT DOMAIN IN THE TRANSMEMBRANE GLYCOPROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS
    GNANN, JW
    NELSON, JA
    OLDSTONE, MBA
    [J]. JOURNAL OF VIROLOGY, 1987, 61 (08) : 2639 - 2641
  • [29] DETERMINANTS OF ANTIBODY-RESPONSE AFTER RECOMBINANT GP160 BOOSTING IN VACCINIA-NAIVE VOLUNTEERS PRIMED WITH GP160-RECOMBINANT VACCINIA VIRUS
    GRAHAM, BS
    GORSE, GJ
    SCHWARTZ, DH
    KEEFER, MC
    MCELRATH, MJ
    MATTHEWS, TJ
    WRIGHT, PF
    BELSHE, RB
    CLEMENTS, ML
    DOLIN, R
    COREY, L
    BOLOGNESI, DP
    STABLEIN, DM
    ESTERLITZ, JR
    HU, SL
    SMITH, GE
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (04) : 782 - 786
  • [30] Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines
    Graham, BS
    McElrath, MJ
    Connor, RI
    Schwartz, DH
    Gorse, GJ
    Keefer, MC
    Mulligan, MJ
    Matthews, TJ
    Wolinsky, SM
    Montefiori, DC
    Vermund, SH
    Lambert, JS
    Corey, L
    Belshe, RB
    Dolin, R
    Wright, PF
    Korber, BT
    Wolff, MC
    Fast, PE
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (02) : 310 - 319